0NN Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Avicanna Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.17 |
| 52 Week High | CA$0.32 |
| 52 Week Low | CA$0.12 |
| Beta | 0.27 |
| 1 Month Change | 9.15% |
| 3 Month Change | 5.03% |
| 1 Year Change | 4.38% |
| 3 Year Change | -37.22% |
| 5 Year Change | -86.08% |
| Change since IPO | -92.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.8% | 2.0% | -0.9% |
| 1Y | 4.4% | -25.8% | 14.1% |
Return vs Industry: 0NN exceeded the German Pharmaceuticals industry which returned -26.3% over the past year.
Return vs Market: 0NN underperformed the German Market which returned 15.8% over the past year.
Price Volatility
| 0NN volatility | |
|---|---|
| 0NN Average Weekly Movement | 21.4% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 0NN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0NN's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 87 | Aras Azadian | www.avicanna.com |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. The company commercializes approximately thirty proprietary evidence-based finished products. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
Avicanna Inc. Fundamentals Summary
| 0NN fundamental statistics | |
|---|---|
| Market cap | €20.09m |
| Earnings (TTM) | -€1.62m |
| Revenue (TTM) | €16.25m |
Is 0NN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NN income statement (TTM) | |
|---|---|
| Revenue | CA$25.34m |
| Cost of Revenue | CA$11.83m |
| Gross Profit | CA$13.51m |
| Other Expenses | CA$16.03m |
| Earnings | -CA$2.53m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.023 |
| Gross Margin | 53.31% |
| Net Profit Margin | -9.97% |
| Debt/Equity Ratio | 0% |
How did 0NN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 20:10 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avicanna Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rahul Sarugaser | Raymond James Ltd. |